Key Takeaways From Inari Medical Analyst Ratings
Portfolio Pulse from Benzinga Insights
Inari Medical (NASDAQ:NARI) has received mixed analyst ratings over the last quarter, with a range of bullish to bearish sentiments. The average 12-month price target has decreased by 2.83% to $56.75. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance. Inari Medical, a medical device company, has shown a 22.53% revenue growth rate but faces challenges with a net margin of -21.5% and an ROA of -4.7%.
October 29, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Inari Medical has received mixed analyst ratings, with a slight decrease in the average price target to $56.75. The company shows strong revenue growth but faces profitability challenges.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on Inari Medical's stock price. The company's strong revenue growth is a positive indicator, but challenges in profitability and asset utilization may offset this, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100